提供了具有以下结构(I)的化合物或其药物可接受的盐、互变异构体或立体异构体，其中1a 1b 2a 2b 3a 3b 4a 4b 5 6 7 8 9R 、R 、R 、R 、R 、R 、R 、R 、R、R、R、R、R、L1、L2、a、b、c、d和e如本文定义。还提供了所述化合物作为用于递送治疗剂的脂质纳米颗粒制剂组分的用途，包含所述化合物的组合物，及其使用和制备方法。(56)对比文件Christopher J.COOK等“.Synthesis andCharacterization of Cis-Sioxomolybdenum(VI) Complexes with Sterically BulkyTripodal Tetradentate Ligands”.《Inorganica Chimica Acta》.1998,第144卷C. J. Cattanach, A. Cohen等.“Studiesin the lndole Series. Part 1V.lTetrahydro-I H-pyrido[4,3-6]-indoles asSerotonin Antagonists”《.J. Medicin.Chem》.1966,第9卷Christopher A. Alabi等.“Multiparametric approach for theevaluation of lipid nanoparticles forsiRNA delivery”《.Proceedings of theNational Academy of Science》.2013,第110卷(第32期),Benoıˆt Frisch等“.A New TriantennaryGalactose-Targeted PEGylated GeneCarrier, Characterization of Its Complexwith DNA, and Transfection of HepatomaCells”《.Bioconjugate Chem.》.2004,第15卷